Home > Boards > US OTC > Medical - Drugs > Regenex Biopharmaceuticals (RGRX)

$RGRX ~ RegeneRx Biopharmaceuticals, Inc. due diligence report

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
$Pistol Pete$ Member Profile
Member Level 
Followed By 2,320
Posts 238,539
Boards Moderated 58
Alias Born 05/06/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 9/30/2019 5:00:57 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 9/10/2019 5:06:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 8/30/2019 5:01:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/28/2019 2:30:04 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 8/21/2019 5:06:45 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/15/2019 11:56:23 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/15/2019 11:54:42 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2019 4:03:31 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/17/2019 4:10:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:10:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:08:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:08:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:07:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:06:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 4:06:14 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/16/2019 4:19:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 4:18:14 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/16/2019 11:22:09 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/16/2019 11:21:04 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:20:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:19:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/15/2019 5:19:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:08:59 PM
$Pistol Pete$ Member Level  Sunday, 12/13/15 09:59:02 PM
Re: The Night Stalker post# 189
Post # of 225 
$RGRX ~ RegeneRx Biopharmaceuticals, Inc. due diligence report

$RGRX recent news/filings

## source: finance.yahoo.com

Tue, 08 Dec 2015 18:18:19 GMT ~ REGENERX BIOPHARMACEUTICALS INC Financials


read full: http://finance.yahoo.com/q/is?s=rgrx
*********************************************************

Fri, 04 Dec 2015 15:12:43 GMT ~ RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

[at noodls] - ROCKVILLE, Md., Dec. 4, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ('the Company' or 'RegeneRx'), a clinical-stage drug development company focused on tissue protection, repair ...

read full: http://www.noodls.com/view/C83F2CAC40F61632715754486760FCEFFB93E4C8
*********************************************************

Fri, 04 Dec 2015 14:39:00 GMT ~ RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

[PR Newswire] - ROCKVILLE, Md., Dec. 4, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the Chinese State Intellectual Property Office (SIPO) has issued a patent for a key peptide fragment of Thymosin beta 4 (TB4) to RegeneRx. "This is one of two biologically active peptide fragments of TB4 that we are interested in because, as demonstrated in a number of animal models, we believe they have properties potentially useful in medical and cosmeceutical product candidates. We are pleased that we received this patent in China, which has significant market potential for such products," stated Dr. Allan L. Goldstein, Emeritus Professor and Chairman of the Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and RegeneRx's chief scientific advisor.

read full: http://finance.yahoo.com/news/regenerx-receives-chinese-patent-key-143900419.html
*********************************************************

Fri, 13 Nov 2015 21:13:02 GMT ~ REGENERX BIOPHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/151113/rgrx10-q.html
*********************************************************

Wed, 28 Oct 2015 14:17:06 GMT ~ RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC

[at noodls] - ROCKVILLE, Md., Oct. 28, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced ...

read full: http://www.noodls.com/view/970D40E69F79018E2B057E55EE64CA224F431748
*********************************************************

$RGRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$RGRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RGRX/company-info
Ticker: $RGRX
OTC Market Place: OTCQB
CIK code: 0000707511
Company name: RegeneRx Biopharmaceuticals, Inc.
Company website: http://www.regenerx.com/wt/home/index
Incorporated In: DE, USA

Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:24,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:11,2:10,3:8,4:12,5:3,6:25,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){if(window.addEventListener){var e=t("handle"),n=t("ee");t(1),window.addEventListener("click",function(){e("inc",["ck"])},!1),window.addEventListener("hashchange",function(){e("inc",["hc"])},!1),n.on("pushState-start",function(){e("inc",["ps"])})}},{1:9,ee:"QJf3ax",handle:"D5DuLP"}],6:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],7:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3);var a=Event;n.on("fn-start",function(t){var e=t[0];e instanceof a&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof a&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:11,2:10,3:9,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],8:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=t("ee").create(),i=t(1)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t,e){function n(){return s}if(t[1]){var r=t[1];if("function"==typeof r){var s=a(r,"nr@wrapped",function(){return i(r,"fn-",n,r.name||"anonymous")});this.wrapped=t[1]=s,o.emit("initEventContext",[t,e],this.wrapped)}else"function"==typeof r.handleEvent&&i.inPlace(r,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:26,ee:"QJf3ax",gos:"7eSDFh"}],9:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState","replaceState"],"-")},{1:26,ee:"QJf3ax"}],10:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:26,ee:"QJf3ax"}],11:[function(t,e){function n(t,e,n){t[0]=i(t[0],"fn-",null,n)}function r(t,e,n){function r(){return a}this.ctx={};var a={"nr@context":this.ctx};o.emit("initTimerContext",[t,n],a),t[0]=i(t[0],"fn-",r,n)}var o=t("ee").create(),i=t(1)(o);e.exports=o,i.inPlace(window,["setTimeout","setImmediate"],"setTimer-"),i.inPlace(window,["setInterval"],"setInterval-"),i.inPlace(window,["clearTimeout","clearImmediate"],"clearTimeout-"),o.on("setInterval-start",n),o.on("setTimer-start",r)},{1:26,ee:"QJf3ax"}],12:[function(t,e){function n(){f.inPlace(this,p,"fn-",o)}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),e.hasOwnProperty("addEventListener")&&u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:8,2:26,ee:"QJf3ax"}],13:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1),u=window.XMLHttpRequest;t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof u&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof u&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:14,3:12,4:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],14:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],15:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:24,2:25,handle:"D5DuLP"}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):void(r.q&&(r.q[t]||(r.q[t]=[]),r.q[t].push(e)))}var r=t("ee").create();e.exports=n,n.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=window,f=c.document;t(2);var u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-768.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:24,2:15,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],24:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],25:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r


$RGRX share structure

## source: otcmarkets.com

Market Value: $39,131,435 a/o Dec 11, 2015
Shares Outstanding: 101,640,092 a/o Aug 14, 2015
Float: 45,819,317 a/o May 14, 2015
Authorized Shares: 200,000,000 a/o May 14, 2015
Par Value: 0.001
$RGRX extra dd links

Company name: RegeneRx Biopharmaceuticals, Inc.
Company website: http://www.regenerx.com/wt/home/index

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RGRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RGRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RGRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/news - http://finance.yahoo.com/q/h?s=RGRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RGRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RGRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RGRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=RegeneRx+Biopharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=RegeneRx+Biopharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=RegeneRx+Biopharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.regenerx.com/wt/home/index
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.regenerx.com/wt/home/index#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.regenerx.com/wt/home/index

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RGRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000707511&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RGRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RGRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RGRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RGRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RGRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RGRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RGRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RGRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RGRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RGRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RGRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RGRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RGRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RGRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RGRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RGRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RGRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RGRX


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist